Turkish Journal of Medical Sciences
Volume 31

Number 2

Article 7

1-1-2001

Immunohistochemical Expression of C-Erb-B2, Steroid Receptors
and Cathepsin-D in Breast Carcinomas: A Clinicopathologic Trial
HADİCE ELİF PEŞTERELİ
OKAN ERDOĞAN
BAHAR KILIÇARSLAN
TANER ÇOLAK
EVREN TERCAN

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
PEŞTERELİ, HADİCE ELİF; ERDOĞAN, OKAN; KILIÇARSLAN, BAHAR; ÇOLAK, TANER; TERCAN, EVREN;
AKAYDIN, MUSTAFA; and KARAVELİ, ŞEYDA (2001) "Immunohistochemical Expression of C-Erb-B2,
Steroid Receptors and Cathepsin-D in Breast Carcinomas: A Clinicopathologic Trial," Turkish Journal of
Medical Sciences: Vol. 31: No. 2, Article 7. Available at: https://journals.tubitak.gov.tr/medical/vol31/
iss2/7

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Immunohistochemical Expression of C-Erb-B2, Steroid Receptors and CathepsinD in Breast Carcinomas: A Clinicopathologic Trial
Authors
HADİCE ELİF PEŞTERELİ, OKAN ERDOĞAN, BAHAR KILIÇARSLAN, TANER ÇOLAK, EVREN TERCAN,
MUSTAFA AKAYDIN, and ŞEYDA KARAVELİ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol31/iss2/7

Turk J Med Sci
31 (2001) 131-136
© TÜB‹TAK

Hatice Elif PEfiTEREL‹1
Okan ERDO⁄AN2
Bahar KILIÇARSLAN1
Taner ÇOLAK2
Evren TERCAN3
Mustafa AKAYDIN3
fieyda KARAVEL‹1

Immunohistochemical Expression of C-Erb-B2,
Steroid Receptors and Cathepsin-D in Breast
Carcinomas: A Clinicopathologic Trial

Received: August 18, 2000

Abstract: Aim: We investigated the role of cerb-B2, hormone receptors and cathepsin D
in breast carcinoma progression and their
correlation with each other.
Methods: Forty-six breast carcinoma
patients, operated on in the deparment of
surgery and diagnosed in the pathology
department, were classified according to
their histopathological characteristics; the
results of immunostaining with estrogen and
progesterone receptors, c-erb-B2 and
cathepsin-D were correlated with the stage
and the disease-free survival of the patients.
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3Biostatistics, Faculty of Medicine Akdeniz
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Results: Nuclear positivity was observed in
23 (50 %) cases for estrogen receptor and in
16 (34.8 %) cases for progesterone
receptor. There was membranous staining
with c-erb-B2 in 37 (80.4 %) cases and

Introduction
In the last few years, in addition to research into wellknown clinicopathological factors like patient age, tumour
size, axillary node status and hormone receptors, there
have been a lot of studies concerning the biological
factors that affect tumour behavior and also some that
have attempted to explain the carcinogenesis in breast
carcinoma. A cell-surface growth receptor and
protooncogene c-erb-B2 overexpression which is said to
have an adverse effect on prognosis, and also influences
the response to chemotherapy, is one of these factors (1).
C-erb-B2 gene amplif›cation has been observed in 1040% of breast carcinomas (2). Cathepsin-D, an aspartyl
protease, is one of the factors that determine the invasion
and the metastatic capacity of the tumour. It also has a
mitogenic effect, in addition to its estrogen induced
proteolytic activity 3. With all these effects on tumour

cytoplasmic staining with cathepsin-D in 44
(95.6 %) cases. Cathepsin-D positivity was
significantly related to the axillary lymph
node metastases (p<0.001). A positive
correlation was observed between c-erb-B2
and cathepsin-D positivity and also between
estrogen and progesterone receptors
(r=0.45, p<0.001).
Conclusion: The results of this study revealed
a high incidence of c-erb-B2 oncogene
overexpression in breast carcinomas from
Turkish mediterranean women. Cathepsin-D
positivity of the tumor cells was correlated
with the lymph node metastases. Only
estrogen receptor positivity was correlated
with the stage of the tumour (p=0.02071).
Key Words: Breast carcioma, cathepsin-D, cerb-B2

behavior, it is thought that the positivity of cathepsin-D in
tumour and stromal cells influences the disease free and
overall survival of the patient. We investigated the
relationship between these two markers (c-erb-B2 and
cathepsin-D), hormone status and clinicopathologic
findings; at the same time, we tried to determine whether
there was any correlation between these factors. The
signif›cance of these factors was analysed by the KaplanMeier method.
Materials and Methods
Fourty-six patients who had undergone modified
radical mastectomy at the surgery department and who
had been diagnosed as having inf›ltrative breast
carcinoma at the pathology department were included in
this study. The ages of the patients ranged from 40 to 73
(mean 50.8) years old. On histopathological examination,
131
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25 of the 46 patients were revealed as having infiltrative
ductal tumours, 8 had inf›ltrative ductal and lobular
tumours , 5 had inf›ltrative lobular tumours, 2 had
medullary tumours, 2 had mucinous tumours, 2 had
apocrine tumours, 1 signet ring cell tumours and there
was 1 carcinoma with neuroendocrine differentiation.
The tumours were greater than 2 cm in 32 (69.6 %)
cases and smaller or equal to 2 cm in 14 (30.4 %).
Staging was done according to UICC4
and the
clinicopathologic f›ndings are summarized in Table 1.
Immunohistochemical staining was performed on
paraff›n-embedded tissue sections fixed with buffered
formalin. Sections of 4µm thickness were mounted on
poly-L-lysine coated slides, deparaffinized and hydrated
through graded alcohols to water. Optimum
pretreatment and dilutions were determined by testing
with both known positive and negative material. The
slides were microwaved in citrate buffer for 10 min in an
800 W microwave oven for antigen retrieval, then
allowed to cool for 20 min. The slides were stained with
a Dako TechMate 500 automated immunostainer using
the standard strepavidin-biotin method. The primary
antibodies used are listed in Table 2. Following the
endogenous peroxide and protein blocking step, the slides
were incubated with primary antibodies for 45 min. After
brief washes, they were incubated in a cocktail of

Table 1.

Clinicopathologic characteristics of the patients

Histophologic type (n:46)
Infiltrative ductal carcinoma
Infiltrative lobular carcinoma
Infiltrative ductal+ lobular
Medullary carcinoma
Apocrine carcinoma
Mucinous carcinoma
Signet ring cell carcinoma
Carcinoma with neuroendocrine differentiation
Stage
I
II A
II B
III A
III B
Size of the tumour
< 2 cm
> 2 cm
Lymph node metastases
Positive
Negative
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25
5
8
2
2
2
1
1

(54.3 %)
(10.9 %)
(17.4 %)
(4.3 %)
(4.3%)
(4.3 %)
(2.2 %)
(2.2 %)

1
15
12
16
2

(2.17 %)
(32.6 %)
(26.1 %)
(34.8 %)
(4.3 %)

14
32

(30.4 %)
(69.6 %)

34
12

(73.9 %)
(26.1 %)

Table 2.

List of the antibodies used

Antibodies
Estrogen receptor
Progesterone receptor
C-erb-B2
Cathepsin-D

Dilution

Source

1:50
1:10
1:50
1:50

Dako
Dako
Dako
Dako

biotinylated anti-mouse IgG/IgM and anti-rabbit IgG for
30 min. The sections were then washed and incubated in
streptavidin-biotin complex for 30 min, and reacted with
diaminobenzidine and hydrogen peroxide in order to
examine the end product. Mayer’s haematoxylin was
used as a counterstain. Immunohistochemical reactions
were evaluated semiquantatively for the percentage of
the stained area and the intensity of the staining as
follows: +/mild, ++/moderate, +++/ strong. Staining
more than 5 % of specimen was regarded as positive for
statistical analysis. Nuclear staining for hormone
receptors, membranous for c-erb-B2 and cytoplasmic
staining for cathepsin-D were all evaluated (Figures 1-3).
Positive staining of stromal cells with Cathepsin-D was
not observed.
Statistical Analysis:
Chi-square, Fisher’s Chi-Square and Spearman
correlation tests were used for statistical analysis. The
follow-up period of the patients was between 2 and 40
months (mean 21 months) and the effect of each marker
on the disease-free and overall survival was analysed by a
Kaplan-Meier curve.

Figure 1.

Membranous c-erb-B2 positivity in infiltrative ductal
carcinoma, x400, DAB
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Results

Figure 2.

Cytoplasmic cathepsin-D positivity in infiltrative ductal
carcinoma, x400, DAB

Most of the tumours (54.3 %) were infiltrative
ductal carcinomas, and had lymph node metastases (76.1
%). Estrogen receptor was found to be positive in half of
the carcinomas, whereas progesterone receptor was
positive in 16 of them. Seventeen stage II and 5 stage-III
cases were negative for estrogen receptor; for
progesterone receptor, these values were 17 and 12
respectively. There was only a statistically significant
difference between the estrogen receptor positivity of
stage-II and stage-III carcinomas (p=0.02071). We did
not find any correlation between the progesterone
receptor status and stage or the histopathologic type of
carcinoma. In 12 cases, both estrogen and progesterone
receptors were positive. A significant correlation between
estrogen and progesterone receptor positivity was
(r=0.53, p=0.001).
C-erb-B2 was positive in 37 (80.4 %) of the tumours.
The positivity of c-erb-B2 was even higher, 83.3 % in
stage-III carcinomas, but the differences in c-erb-B2
overexpression between the stages were not significant.
Cathepsin-D was positive in all the tumours except for
two stage-II carcinomas. There were no correlations
between cathepsin-D positivity and the stage or
histopathological type. However, cathepsin-D was
positive in all of the lymph node positive cases and the
difference was statistically significant (p= 0.01449). The
results are summarized in Tables 3,4 and 5.
A positive correlation was found between c-erb-B2
overexpression and cathepsin-D positivity (r=0.45,
p=0.008).

Figure 3a.

Nuclear estrogen receptor positivity in infiltrative ductal
carcinoma, x400, DAB

Five patients had distant organ metastases (lung,
bone), 1 in the 4th year , 2 in the 3rd year, 1 in the 2nd year
and 1 in the 6th month of the postoperative period. All the
carcinomas in these patients showed strong c-erb-B2 and
cathepsin-D positivity (90 %, +++).
Discussion

Figure 3b.

Progesterone receptor positivity in infiltrative ductal
carcinoma,x400, DAB

In this study, we did not find any relationship between
hormone status, c-erb-B2 positivity, cathepsin-D
positivity and the stage of the tumours. There was a
significant difference only in the estrogen receptor
positivity between the stages. In the present study, the
number of the patients at each stage was small. Most of
the tumours (32, 69.6 %) were T2/T3 and node positive
(34, 73.9 %), and this may have affected the results. In
most of the studies in the literature, including that of Van
de Vivjer et al., a positive correlation between neu-protein
overexpression and tumour size was found (5). In our
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Stage II (n: 27)
Estrogen receptor
positive

Stage III (n: 18)

10 (27.1 %)

Table 3.

Stages of the tumours and
immunohistochemical results

Table 4.

Lymph node (LN) status and
immunohistochemical results

13 (72.2 %)
p=0.02071

negative
progesterone receptor
positive

17 (62.9 %)

5 (27.8 %)

10 (27.1 %)

6 (33.3 %)
p=0.79928

negative

17 (62.9 %)

positive

22 (81.5 %)

12 (66.7 %)

C-erb-B2
15 (83.3 %)
p=1.00000
negative
Cathepsin-D
positive

5 (18.5 %)

3 (16.7 %)

25 (92.6 %)

18 (100 %)
p=0.50909

negative

Estrogen receptor
positive

2 (7.4 %)

0 (0 %)

LN + (n:34)

LN - (n:12)

18 (52.9 %)

5 (41.7 %)
p=0.50187

negative
Progesterone receptor
positive

16 (47.1 %)

7 (58.3 %)

13 (38.2 %)

3 (25 %)
p=0.49770

negative

21 (61.8 %)

9 (75 %)

C-erb-B2
positive

28 (82.4 %)

9 (75 %)
p=0.67773

negative
Cathepsin-D
positive

6 (17.6 %)

3 (25 %)

34 (100 %)

9 (75 %)
p=0.01449

negative

0 (0 %)

3 (25 %)

study, all of the T2/T3 tumours exhibited strong cell
membrane positivity for c-erb-B2. Although the rate of cerb-B2 positivity in our patients was much higher than
that in most other studies, we thought that this may be
due to the characteristics of the population that we were
dealing with or due to the c-erb-B2 antibody that we
used. To improve our hypothesis, we will study the same
patients with more sophisticated techniques like PCR and
FISH. Midulla et al., observed c-erb-B2 positivity in 89.4
% of 77 breast carcinoma patients (6).

these two markers using the immunohistoche-mical
method. However, cathepsin-D was positive in all node
positive tumours (34 out of 46 cases) and the difference
between the lymph node positive and negative tumours
was significant (p=0.01449). In the literature, while
some investigators have mentioned the same relationship
(7, 8, 9), others were unable to identify any correlation
between node status and the cathepsin-D positivity of
tumours (10, 11). We propose that cathepsin-D positivity
of the tumour cells reveal aggressive tumour behavior.

Though cathepsin-D is an estrogen-induced protease,
we did not discover any positive relationship between

The correlation between c-erb-B2 and cathepsin-D,
which is known to affect prognosis adversely, also was
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Table 5.

Correlation of hormone status with c-erb-B2 and cathepsin-D

Estrogen
positive

receptor
negative

Progesterone
positive

receptor
negative

19
3

19
5

14
3

23
6

22
1

22
1

16
0

28
2

C-erb-B2
positive
negative
Cathepsin-D
positive
negative

found by Schultz et al., (12). There have also been
reports in the literature that reveal no correlation (13,
14).
The strong positivity of c-erb-B2 and cathepsin-D in
tumours which metastased and also in the tumours of
patients who died of their illness supports studies
showing a negative effect of these two markers on
prognosis (5, 15, 16). However, in studies with
multivariate analysis, there have been conflicting results
with regard to the independent prognostic effect of these
factors (1, 17, 18). In our study, we concluded that cerb-B2 positivity in Turkish Mediterranean patients with
breast carcinoma was extremely high. It could have a
negative effect on tumour behaviour. Tumors with

cathepsin-D positivity might also exhibit aggressive
behaviour, but to prove their role in tumour
aggressiveness, the number of patients must be
increased, and future studies should include at least ten
years of follow-up.
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